OTC use of promethazine
Executive Summary
In a Nov. 27 letter to FDA, Wyeth-Ayerst requested that, if FDA decides to ask the advice of another advisory committee on the safety and efficacy of promethazine for OTC use, it be a special ad hoc panel consisting of members with expertise in SIDS/sleep apnea, pediatric neurology and epidemiology, and a knowledge of the regulatory basis for Rx to OTC switches. In July 1989, an Rx advisory committee overturned FDA's recommended switch for the drug.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.